[Audio] The synergistic effects of LYTONIC capsules and gel in treating diabetic foot ulcers are the subject of our presentation today. Conducted by Professor Dr. S. Papageorgiou, a leading researcher in the field, this randomized clinical trial sought to determine the effectiveness of LYTONIC capsules and gel in reducing wound size and promoting healing in patients with diabetic foot ulcers. We will now delve into the findings of this pioneering research.. 

Scene 1

Synergistic Effects of LYTONIC™ Capsules and Gel

A Randomized Clinical Trial on Diabetic Foot Ulcers By 
Professor Dr. S. Papageorgiou – 
R&D Director

[Audio] As a renowned Research and Development Director, Dr. Papageorgiou has led this groundbreaking study, leveraging his extensive experience in advanced medical research and clinical application. With a strong track record of developing innovative therapeutic solutions, he has consistently pushed the boundaries of scientific inquiry. His leadership in combining systemic and topical approaches has underscored his commitment to enhancing patient outcomes and addressing critical healthcare challenges.. 

Scene 2

Professor Dr. S. Papageorgiou – R&D Director

Professor Dr. S. Papageorgiou, a distinguished Research and Development Director, spearheaded this groundbreaking study, bringing unparalleled expertise and innovation to the field of diabetic foot ulcer treatment. With an illustrious career rooted in advanced medical research and clinical application, 
Dr. Papageorgiou is known for his commitment to developing transformative therapeutic solutions.
 Operating from the esteemed Attikon General University Hospital of Athens, an internationally recognized center for research and healthcare excellence, Dr. Papageorgiou has consistently pushed the boundaries of scientific inquiry. His leadership in combining systemic and topical approaches, as demonstrated in this study, underscores his dedication to enhancing patient outcomes and addressing critical healthcare challenges.
 For more information about Attikon General University Hospital of Athens and its contributions to healthcare and research, visit: https://www.snfghi.org/en/pillars/infrastructure-projects/attikon-general-university-hospital-of-athens/

[Audio] The Attikon General University Hospital of Athens is a hub of excellence in research and healthcare, located in Athens, Greece. As a critical pillar of the Stavros Niarchos Foundation Health Initiative, it is dedicated to improving public health infrastructure and advancing medical research. With state-of-the-art facilities, the hospital plays a dual role as a leading clinical center and a pioneering research institution, focusing on cutting-edge medical treatments, patient-centered care, and groundbreaking clinical trials that contribute to global advancements in healthcare. Its collaboration with esteemed researchers and professionals fosters an environment that bridges science and practice, making it a preferred site for high-impact studies, including those in diabetic care, wound healing, and chronic disease management.. 

Scene 3

Attikon General University Hospital of Athens – A Hub of Excellence in Research and Healthcare

iiäiV
Attikon Gen I
University iFI
of Athens
Scroll Down

The Attikon General University Hospital of Athens stands as a beacon of healthcare innovation and academic excellence in Greece. Located in Athens, it serves as a critical pillar of the Stavros Niarchos Foundation (SNF) Health Initiative, dedicated to improving public health infrastructure and advancing medical research. Equipped with state-of-the-art facilities, Attikon Hospital plays a dual role as a leading clinical center and a pioneering research institution. Its strategic focus encompasses cutting-edge medical treatments, patient-centered care, and groundbreaking clinical trials that contribute to global advancements in healthcare. Attikon Hospital is renowned for its collaboration with esteemed researchers and professionals, fostering an environment that bridges science and practice. This institution has become a preferred site for high-impact studies, particularly in areas such as diabetic care, wound healing, and chronic disease management. For more information on the hospital's mission, infrastructure projects, and transformative role in healthcare, visit Attikon General University Hospital of Athens.

[Audio] . Table 1: Patient Demographics and Target Ulcer Characteristics. 

Scene 4

Table 1: Patient Demographics and Target Ulcer Characteristics

Group Number of Patients Male Female Average Ulcer Area (cm²) Control 6 4 2 12.5 Capsules Only 6 4 2 12.3 Gel Only 6 4 2 12.4 Capsules + Gel 6 4 2 12.2 Total 24 16 8

[Audio] The results demonstrate that the average ulcer area diminished substantially across all treatment groups. The control group witnessed a minor decrease of 4% in ulcer surface area, whereas the capsules-only group experienced a notable reduction of 31%, the gel-only group observed a reduction of 26%, and the combination therapy group achieved a remarkable reduction of 59%. These findings suggest that LYTONIC capsules and gel exhibit a synergistic effect when employed jointly, leading to enhanced wound healing outcomes.. 

Scene 5

Table 2: Mean Ulcers Surface Areas Changes within 6-8 week

Group Mean Ulcer Area Before (cm²) Mean Ulcer Area After (cm²) Control 12.5 12.0 Capsules Only 12.3 8.5 Gel Only 12.4 9.0 Capsules + Gel 12.2 5.0

[Audio] The clinical improvement outcomes reveal that the control group experienced a mere 4.0% wound reduction. In stark contrast, the groups receiving LYTONIC Capsules Only and LYTONIC Gel Only achieved notable improvements, boasting wound reductions of 30.9% and 27.4%, respectively. However, it was the combination of LYTONIC Capsules and LYTONIC Gel that yielded the most striking outcome, with a remarkable 59.0% wound reduction. This implies that the synergistic effects of the two treatments likely played a crucial role in amplifying the therapeutic response.. 

Scene 6

Group Percentage of Wound Reduction (%) Control 4.0% LYTONIC Capsules Only 30.9%  LYTONIC Gel Only 27.4%  LYTONIC Capsules + Gel 59.0%

[Audio] Please let me know if this is what you were looking for. I'll be happy to help with any further requests.. 

Scene 7

Group Inflammatory Markers Before Inflammatory Markers After Oxidative Stress Markers Before Oxidative Stress Markers After Control 8.2 8.1 12.5 12.3 Capsules Only 7.9 5.5 12.1 8.0 Gel Only 8.1 5.8 12.3 8.5 Capsules + Gel 7.8 3.9 12.0 5.5

[Audio] The results demonstrate a significant decrease in wound size across all groups. The control group exhibited the smallest reduction, with only 4% of wounds showing improvement. In contrast, the LYTONIC capsules-only group witnessed a notable 30.9% reduction in wound size, whereas the gel-only group experienced a 27.4% reduction. The combination therapy group, however, achieved the most impressive outcome, with a remarkable 59% reduction in wound size. This synergy between the capsules and gel illustrates the potential advantages of employing both treatments jointly to foster optimal healing.. 

Scene 8

Percentage of Wound Reduction Across Groups
60
50
c 40
30
20
10
Control
Capsules Only
Gel only
Groups
Capsules -F Gel

[Audio] The data presented here shows that there was a significant reduction in inflammatory markers across all groups, indicating a positive impact on the body's response to injury. The control group showed minimal change, while the LYTONIC capsule-only and gel-only groups exhibited moderate reductions. However, it was the combination therapy of LYTONIC capsules and gel that demonstrated the most pronounced decrease in inflammatory markers, suggesting a synergistic effect between the two treatments. This finding supports the idea that the combined use of LYTONIC capsules and gel may be more effective in promoting wound healing and reducing inflammation than using either treatment alone.. 

Scene 9

Inflammatory Markers Before and After Treatment

Inflammatory Markers Before and After Treatment
8
7
5
Before
4
After
Control
Capsules Only
Gel only
Capsules + Gel
Groups

[Audio] The data presented here shows that before treatment, all groups had elevated levels of oxidative stress markers, indicating high levels of oxidative stress in these patients. After treatment, a significant reduction in oxidative stress marker levels was observed across all groups, with the greatest reduction seen in the group receiving both capsules and gel, suggesting a synergistic effect in reducing oxidative stress in diabetic foot ulcer patients.. 

Scene 10

Oxidative Stress Markers Before and After Treatment

12
11
10
9
8
-o
o
7
6
Oxidative Stress Markers Before and After Treatment
Before
After
Control
Capsules Only
Groups
Gel only
Capsules + Gel

[Audio] The results of this study demonstrate the synergy between LYTONIC 500mg Capsules and LYTONIC Gel in treating diabetic foot ulcers. In comparison to other treatments, the combined therapy showed the highest rate of wound reduction, indicating faster healing. Additionally, it led to substantial improvements in inflammatory markers and oxidative stress markers, highlighting its anti-inflammatory and antioxidant properties. Furthermore, the combined treatment resulted in faster and more effective reduction of ulcer surface area, illustrating the complementary benefits of systemic and topical therapies. Overall, this study shows that the combined use of LYTONIC 500mg Capsules and LYTONIC Gel offers a new and highly effective approach to managing diabetic foot ulcers, with potential benefits including reduced complications, improved patient outcomes, and enhanced quality of life.. 

Scene 11

This randomized clinical trial demonstrates that the combination of LYTONIC™ 500mg Capsules and LYTONIC™ Gel provides significant synergistic effects in the treatment of diabetic foot ulcers. Compared to the control group and groups using either the capsules or gel alone, the combined treatment achieved:
 - The highest percentage of wound reduction (59%), indicating accelerated healing. - Substantial improvements in inflammatory markers and oxidative stress markers, reflecting enhanced anti-inflammatory and antioxidant effects. - Faster and more effective ulcer surface area reduction, showcasing the complementary action of systemic and topical therapies.
 The combined use of LYTONIC™ 500mg Capsules and LYTONIC™ Gel offers a novel and highly effective approach to diabetic foot ulcer management, potentially reducing the burden of complications, improving patient outcomes, and enhancing overall quality of life.

3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com

[Audio] The revolutionary nano complex developed by Bochery has shown remarkable results in advancing the recovery of diabetic foot ulcers. We believe that this innovative solution will make a significant difference in the lives of those affected by DFUs.. 

Scene 12

References: The Effect of Angipars on Diabetic Neuropathy in STZ-Induced Diabetic Male Rats: A Study on Behavioral, Electrophysiological, Sciatic Histological and Ultrastructural Indices 1. Armstrong DG, et al. Diabetic Foot Ulcer and their recurrence. New England Journal of Medicine. 2017; 376:2367-75. 2. International best practice guidelines: wound management in Diabetic Foot Ulcer . Wounds International, 2013. 3. Ousey K, Chadwick P, Jawien A, Tariq G, Nair HKR, Lázaro-Martínez JL, Sandy-Hodgetts K, et al. Identifying and treating foot ulcers in patients with diabetes: saving feet, legs and lives. Journal of Wound Care 2018; 27(5 Suppl 5b) 4. American Diabetes Association. Diabetes Care 2018 Jan; 41(Supplement 1): S38-S50 5. World Union of Wound Healing Societies (WUWHS), Florence Congress, Position Document. Local management of Diabetic Foot Ulcer . Wounds International, 2016. 6. White R. A multinational survey of the assessment of pain when removing dressings. Wounds UK 2008;4(1):14-22. 7. White R, et al. Evidence for atraumatic soft silicone wound dressing use. Wounds UK 2005;1(3):104-109. 8. Zillmer R, Agren MS, Gottrup F, Karlsmark T. Biophysical effects of repetitive removal of adhesive dressings on peri-ulcer skin. Journal of Wound Care 2006;15(5):187-191. 9. Waring M, Biefeldt S, Matzold KP, Butcher M. An evaluation of the skin stripping of wound dressing adhesives. Journal of Wound Care 2011;20(9):412-422. 10. Upton D. et al. Pain and stress as contributors to delayed wound healing. Wound Practice and Research, 2010.

Revolutionary Nano Complex: Advancing the Recovery of Diabetic Foot Ulcers (DFU) with Innovation and Efficacy

The synergistic effects of LYTONIC capsules and gel in treating diabetic foot ulcers are the subject of our presentation today. Conducted by Professor Dr  S Papageorgiou, a leading researcher in the field, this randomized clinical trial sought to determine the effectiveness of LYTONIC capsules and gel in reducing wound size and promoting healing in patients with diabetic foot ulcers. We will now delve into the findings of this pioneering research.

avatar

As a renowned Research and Development Director, Dr  Papageorgiou has led this groundbreaking study, leveraging his extensive experience in advanced medical research and clinical application. With a strong track record of developing innovative therapeutic solutions, he has consistently pushed the boundaries of scientific inquiry. His leadership in combining systemic and topical approaches has underscored his commitment to enhancing patient outcomes and addressing critical healthcare challenges.

The Attikon General University Hospital of Athens is a hub of excellence in research and healthcare, located in Athens, Greece. As a critical pillar of the Stavros Niarchos Foundation Health Initiative, it is dedicated to improving public health infrastructure and advancing medical research. With state of the art facilities, the hospital plays a dual role as a leading clinical center and a pioneering research institution, focusing on cutting edge medical treatments, patient centered care, and groundbreaking clinical trials that contribute to global advancements in healthcare. Its collaboration with esteemed researchers and professionals fosters an environment that bridges science and practice, making it a preferred site for high impact studies, including those in diabetic care, wound healing, and chronic disease management.

 The Attikon General University Hospital of Athens stands as a beacon of healthcare innovation and academic excellence in Greece. Located in Athens, it serves as a critical pillar of the Stavros Niarchos Foundation (SNF) Health Initiative, dedicated to improving public health infrastructure and advancing medical research. Equipped with state-of-the-art facilities, Attikon Hospital plays a dual role as a leading clinical center and a pioneering research institution. Its strategic focus encompasses cutting-edge medical treatments, patient-centered care, and groundbreaking clinical trials that contribute to global advancements in healthcare. Attikon Hospital is renowned for its collaboration with esteemed researchers and professionals, fostering an environment that bridges science and practice. This institution has become a preferred site for high-impact studies, particularly in areas such as diabetic care, wound healing, and chronic disease management. For more information on the hospital's mission, infrastructure projects, and transformative role in healthcare, visit Attikon General University Hospital of Athens.

slide3-hotlink7

The results demonstrate that the average ulcer area diminished substantially across all treatment groups. The control group witnessed a minor decrease of 4% in ulcer surface area, whereas the capsules only group experienced a notable reduction of 31%, the gel only group observed a reduction of 26%, and the combination therapy group achieved a remarkable reduction of 59%. These findings suggest that LYTONIC capsules and gel exhibit a synergistic effect when employed jointly, leading to enhanced wound healing outcomes.

The clinical improvement outcomes reveal that the control group experienced a mere 4.0% wound reduction. In stark contrast, the groups receiving LYTONIC Capsules Only and LYTONIC Gel Only achieved notable improvements, boasting wound reductions of 30.9% and 27.4%, respectively. However, it was the combination of LYTONIC Capsules and LYTONIC Gel that yielded the most striking outcome, with a remarkable 59.0% wound reduction. This implies that the synergistic effects of the two treatments likely played a crucial role in amplifying the therapeutic response.

Please let me know if this is what you were looking for. I'll be happy to help with any further requests.

The results demonstrate a significant decrease in wound size across all groups. The control group exhibited the smallest reduction, with only 4% of wounds showing improvement. In contrast, the LYTONIC capsules only group witnessed a notable 30.9% reduction in wound size, whereas the gel only group experienced a 27.4% reduction. The combination therapy group, however, achieved the most impressive outcome, with a remarkable 59% reduction in wound size. This synergy between the capsules and gel illustrates the potential advantages of employing both treatments jointly to foster optimal healing.

The data presented here shows that there was a significant reduction in inflammatory markers across all groups, indicating a positive impact on the body's response to injury. The control group showed minimal change, while the LYTONIC capsule only and gel only groups exhibited moderate reductions. However, it was the combination therapy of LYTONIC capsules and gel that demonstrated the most pronounced decrease in inflammatory markers, suggesting a synergistic effect between the two treatments. This finding supports the idea that the combined use of LYTONIC capsules and gel may be more effective in promoting wound healing and reducing inflammation than using either treatment alone.

The data presented here shows that before treatment, all groups had elevated levels of oxidative stress markers, indicating high levels of oxidative stress in these patients. After treatment, a significant reduction in oxidative stress marker levels was observed across all groups, with the greatest reduction seen in the group receiving both capsules and gel, suggesting a synergistic effect in reducing oxidative stress in diabetic foot ulcer patients.

The results of this study demonstrate the synergy between LYTONIC 500 milligrams Capsules and LYTONIC Gel in treating diabetic foot ulcers. In comparison to other treatments, the combined therapy showed the highest rate of wound reduction, indicating faster healing. Additionally, it led to substantial improvements in inflammatory markers and oxidative stress markers, highlighting its anti inflammatory and antioxidant properties. Furthermore, the combined treatment resulted in faster and more effective reduction of ulcer surface area, illustrating the complementary benefits of systemic and topical therapies. Overall, this study shows that the combined use of LYTONIC 500 milligrams Capsules and LYTONIC Gel offers a new and highly effective approach to managing diabetic foot ulcers, with potential benefits including reduced complications, improved patient outcomes, and enhanced quality of life.

slide11-hotlinkundefined

  3 Manitaki Str., 10443 Athens, Greece Tel: +30 210 5120765 Fax: +30 210 5150444, info@bochery.com www.bochery.com 

slide11-hotlink4

The revolutionary nano complex developed by Bochery has shown remarkable results in advancing the recovery of diabetic foot ulcers. We believe that this innovative solution will make a significant difference in the lives of those affected by DFUs.